Delving into the Latest Updates on Loureirin A with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Reactive oxygen species

Mechanism

Reactive oxygen species stimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Helicobacter pylori infection

Inactive Indication-

Originator Organization

Nanjing Medical University

Active Organization

Nanjing Medical University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Parkinson's disease (PD) is a type of chronic neurodegenerative disorder. There is an ongoing need for the development of new medications to address this illness. Loureirin C is known to have a protective impact on neurological disorders. Nonetheless, its specific function in Parkinson's Disease (PD) has yet to be fully understood. In this study, we examined the effects of Loureirin C in a cellular model of PD. The PD cell model was established by treating PC-12 cells with 6-hydroxydopamine (6-OHDA). We revealed that Loureirin C promoted the growth of 6-OHDA-treated PC-12 cells. In addition, Loureirin C suppressed the apoptosis of 6-OHDA-treated PC-12 cells and alleviated ferroptosis. Further, Loureirin C improved mitochondrial membrane potential in 6-OHDA-treated PC-12 cells. Mechanically, Loureirin C mediated Nrf2 pathway. Accordingly, Loureirin C not only inhibits ferroptosis but also apoptosis in the 6-OHDA-induced PD cell model, leading us to consider the potential value of Loureirin C in the treatment of PD.

100 Deals associated with Loureirin A

Login to view more data